PharmiWeb.com - Global Pharma News & Resources

Today Stories

Ambulance crews in London have responded to almost 40 suicides or suicide attempts a day this year.The shocking figures come as tonight’s episode of the hit BBC TV show ‘Ambulance’ features a mum who calls 999 after finding her 36-year-old son hanging.Call handler Carly tells Ursula how to give her son chest compressions as ambulance crews are sent to their home. When advanced paramedic Kevin arrives he realises they cannot save Daniel. Instead he comforts Ursula as she says goodbye to her son.Kevin said: “I have certainly seen an increase in suicide over the past 20 years. The majority of them tend to be male.“You feel an empathy for the family members for what they are going through and the heartache they are going to suffer.“We haven’t found all the answers in dealing with mental health…
Alphega Pharmacy has launched a new app, developed in conjunction with Healthera for its network of over 1,000 pharmacy members. The patient-facing app, which is available to download to any mobile device, is designed with the patient in mind, as more and more people turn to digital solutions to fulfil their prescriptions and other healthcare service requirements. The Alphega Pharmacy app uses the UK‟s market leading technology platform for patients and pharmacies. The app offers a seamless digital patient experience, enabling Alphega Pharmacy members to compete with the ever growing list of competitors who offer a digital service for prescription ordering. The impact of COVID-19 has changed shopper habits with more and more people now using digital channels to shop online or engage with t…
The multi award-winning medical technology innovator ‘TestCard’, which allows people to diagnose common conditions and diseases using the camera on their mobile phone, has secured £4.5m in its latest funding round.  Secured via corporate finance and venture capital firm ‘West Hill’, TestCard will use the new wave of funding for new product development, advancing regulatory applications, international expansion and further product launches. It will also help bridge the business through to its Series ‘A’ round, currently anticipated for the second quarter of 2021. With the aim of giving people control over their health and taking further strain off the NHS, Testcard’s ground-breaking at-home UTI testing kit, which launches in November, turns a smartphone camera into a clinical grade scanner,…
London, 20 October 2020: GPDQ, the UK’s leading on-demand GP service, today announces the launch of London’s first private drive thru Covid-19 testing facility operating with immediate effect.  Following the wide spread demand for Covid-19 PCR tests, with people all over the country unable to receive tests in a timely manner, GPDQ has launched the service in London to meet this increased demand. If people are experiencing Covid-19 symptoms, patients can book a 10 minute slot at the site in Hadley Wood using GPDQ’s online system, and the test will then be conducted using swabs on-site at the centre. Should the 24 hour result come back positive, as part of the service you will be called by a GP who will provide a consultation on how best to manage your symptoms and address and concerns the p…
UK-based Contract Research Organisation (CRO) Gentronix – the largest independent genetic toxicology CRO in Europe - has appointed a new Operations Director to accelerate its strategic growth plans.  Laura Hinton, whose previous role was as Director of Scientific Operations at Cyprotex, will join the senior executive team working alongside fellow Operations Director Nick Billinton to facilitate a ‘scale at pace’ growth strategy for the business in line with burgeoning market demand as well as growth into new markets and service areas. As a leading predictive toxicology contract research organisation, Gentronix’s work helps develop safe products used by millions of people around the world including pharmaceuticals, agrochemicals, fragrances, foods and cosmetics. The business has a specialis…
Survey of NHS Child and Adolescent Mental Health Services (CAMHS) in England Key highlights: Almost 4 out of 10 (36.36 percent) of CAMHS have not adopted any new digital mental health tools to support children in need of mental health support since the onset of COVID-19. The majority (63.64 percent) of NHS CAMHS are signposting children and young people (CYP) to an online resource - rather than a proven digital intervention. 45.4 percent of NHS CAMHS believe digital therapeutics have a role to play in early intervention support. LONDON, Oct. 15, 2020, A survey of 135 NHS CCGs in England carried out by BfB Labs, a pioneer in the development of evidence-based digital therapeutics for CYP shows that almost 4 out of 10 NHS CCGs have not implemented any new digital therapeutics to support chi…
Online therapy provider Healingclouds has taken home the award for Best Mental Healthcare Platform 2020 in the SME UK Enterprise Awards. The awards celebrate a multitude of exciting and vibrant businesses and industries in small and medium enterprises. This year the team at web-based therapy platform Healingclouds have been recognised for their work in the mental health space.  Breaking down barriers people face when seeking help and support is top priority for the service, which connects users to a pool of therapists via video call, with 60 to 90 minute sessions from as little as £35. A range of therapies are available from approved and accredited practitioners, including cognitive behaviour therapy (CBT), psychological counselling and psychotherapy. Users can address a number of concerns…
A method for detecting traumatic brain injury at the point of care has been developed by scientists at the University of Birmingham. Using chemical biomarkers released by the brain immediately after a head injury occurs, researchers are able to pinpoint when patients need urgent medical attention. This saves time in delivering vital treatment and avoids patients undergoing unnecessary tests where no injury has occurred. The technique was developed by multi-disciplinary team of researchers in the group of Advanced Nanomaterials, Structures and Applications (ANMSA) led by Dr Goldberg Oppenheimer at the University of Birmingham. Following a proof-of-concept study, the group has now completed Innovate UK’s commercialisation programme, iCURE, to identify commercialisation routes for the techniq…
Gilead Sciences and the European Commission today signed a joint procurement agreement (JPA) that will enable rapid and equitable access to Veklury (remdesivir), the first antiviral licensed for the treatment of COVID-19 in the European Union (EU) and the UK. The JPA enables 37 participating countries in the EU and the European Economic Area (EEA) and the UK to purchase Veklury to address increasing demand and to start to address stockpiling needs, coordinated by the European Commission. The agreement covers purchases of Veklury over the next six months and has the option to be extended. The JPA replaces an Emergency Support Instrument (ESI) that enabled the European Commission to procure Veklury for EU Member States and the UK, from August through October 2020. In the UK, Veklury is indic…
Anti-viral Alphabodies act by inhibiting viral cell fusion New class of Alphabodies with prophylactic and therapeutic potential Hasselt, Belgium, September 7, 2020 – Complix, a biopharmaceutical company developing a pipeline of transformative Alphabody therapeutics announces that it has been awarded a €1.2 million grant (approximately USD$1.4 million) from the Flanders government through the Flemish Agency for Innovation & Entrepreneurship (VLAIO). This grant will allow Complix to accelerate the discovery and development of a novel and differentiating class of Alphabody based therapeutics against coronavirus infections.  Alphabodies represent an ideal scaffold to target the viral cell fusion mechanism based on their exceptional biophysical and structural properties. The cell fusion mec…
Secretary of State for Business, Energy and Industrial Strategy, Alok Sharma, underscores the importance of establishing a domestic manufacturing base from scratch Tuesday 6th October 2020, Harwell, Oxfordshire: Announced today by the Vaccines Manufacturing and Innovation Centre (VMIC), the UK Medicines & Healthcare products Regulatory Agency (MHRA) has now approved the second of two GMP manufacturing suites that house VMIC’s specialist vaccines manufacturing equipment - resulting in two fully equipped, approved manufacturing suites to make a leading COVID-19 vaccine candidate. As part of the national response to develop vaccine for COVID-19, the two suites established with VMIC equipment will be operating at 1000L scale and will be dedicated to the manufacture of a leading COVID-19…
Kancera AB (Nasdaq First North Premier Growth Market: KAN) announces that screening of covid-19 patients for the clinical phase II study of KAND567 starts today. The study, which is carried out in collaboration with Capio St. Göran's Hospital and Petter Brodin's research group at SciLifeLab, aims to study the effect of KAND567 on the immune system, lung function and rehabilitation. Results from the study will be analyzed and communicated on two occasions, the first after all patients have undergone sampling after day 7, and the second after day 90. Kancera develops drugs that counteract damage in acute and chronic inflammation. The Fractalkine blocker KAND567 is primarily developed to effectively counteract hyper-inflammation in various disease states and thereby protect vital organs, e.g.…
The Chief Executive of the UK’s pharmaceutical industry association has today warned MPs about the consequences of not agreeing a comprehensive post-Brexit trade deal or an urgent agreement on medicines while the trade talks continue. Richard Torbett told the Commons EU Future Relationship Committee that negotiators must consider the impact of causing unnecessary disruption and delays for UK and EU medicines whilst in the midst of a global pandemic. The Committee heard that companies were working in a constant state of emergency with supply chains under incredible pressure from COVID-19: "We need the bare minimum in order to safeguard risk to the supply chain [for medicines]. If we don’t get this there will be increased complexity, duplication and cost – the last thing we need during COVI…
It’s been 6 months since PharmiWeb, Europe’s largest pharma job board, launched our job board in Australia. Despite the backdrop of COVID-19, a massive thanks go out to all of our clients and all of the talented individuals who have engaged with our site, and come on board!We’re looking forward to the next 6 months as we continue to raise PharmiWeb’s profile across the continent, and help more and more Australian Life Sciences organisations recruit the best talent from PharmiWeb's ever-growing talent pool.If you would like more information regarding Pharmiweb and what our unique services can do for you, contact Sue or Laurel:Sue van Vuurensue.vanvuuren@pharmiweb.comTel: +61 (0) 468 625 626Laurel Steynlaurel.steyn@pharmiweb.comTel: +61 (0) 423 665 441Find Out More Here #pharmiweb #pharmajob…
*Principia Biopharma Inc. is now a wholly owned subsidiary of Sanofi PARIS – September 28, 2020 – Sanofi announced today the successful completion of its acquisition of Principia Biopharma Inc. (“Principia”) for $100 per share in cash. “The Principia acquisition further strengthens our core areas of autoimmune and allergic diseases, giving us full control of tolebrutinib (SAR442168), as well as additional BTK inhibitors to further develop,” said Paul Hudson, Sanofi Chief Executive Officer. “The Principia integration into Sanofi augments our small molecule research capabilities as we look to maintain leadership in the discovery and development of oral medicines for serious illnesses.” The tender offer for all of the outstanding shares of Principia common stock expired as scheduled at one mi…
After months of waiting, the official NHS COVID-19 contact tracing app for England and Wales is now available.   Protect your loved ones with the official NHS COVID-19 contact tracing app for England and Wales. It's the fastest way of knowing when you're at risk from coronavirus (COVID-19). The quicker you know, the quicker you can alert your loved ones, and your community.  The more of us that use it, the better we can control coronavirus. Protect your loved ones. Please download the app.
World Pharmacists Day is coordinated by the International Pharmaceutical Federation to encourage pharmacists to promote and advocate for the role of the pharmacist in improving healthy living in every corner of the world. “Transforming global health” is the theme of this year’s World Pharmacists Day designed to show how pharmacists contribute to a world where everyone benefits from access to safe, effective, quality and affordable medicines and health technologies, as well as from pharmaceutical care services.
Inflazome is a pioneering inflammasome company developing orally available NLRP3 inflammasome inhibitors to address clinical unmet needs across a wide variety of inflammatory diseases   Acquisition of Inflazome gives Roche full rights to the Inflazome portfolio   Activation of the NLRP3 inflammasome in the body is implicated in many diseases caused by chronic, uncontrolled inflammation   Inflazome shareholders received €380 million upfront, and are eligible to receive additional milestone payments   Dublin (IE), Cambridge (UK), 21 September 2020: Inflazome announced today that it has closed a share purchase agreement with Roche (SIX: RO, ROG; OTCQX: RHHBY) in which Inflazome’s shareholders received an upfront payment of €380 million, and are eligible to receive additional conting…
World Alzheimer’s Day 2020 (21 September) serves as a timely reminder that drug development in this space is slow, as the Alzheimer’s disease (AD) drug market in its current form is marked by an overwhelming need for disease modifying therapies (DMTs) and a more diverse set of treatment options for patients who are experiencing cognitive symptoms or agitation related to dementia, says GlobalData, a leading data and analytics company. According to GlobalData’s report, ‘Alzheimer’s Disease: Global Drug Forecast and Market Analysis to 2028’, the AD market will grow from $2.2bn in 2018 across the eight major markets (*8MM) to $12.9bn in 2028 at a compound annual growth rate (CAGR) of 19.3%. This growth will be driven by the increasing prevalence of the condition worldwide and the introduction…
Following new lockdown restrictions having come into force, Professor Martin Michaelis and Dr Mark Wass of University of Kent’s School of Biosciences explain why we need to adapt to live with the coronavirus to have a proper Christmas: 15 September 2020 ‘Restricting private meetings to six members from multiple households is a significant change of tone, after Boris Johnson recently raised hopes of a “normal” Christmas. The change is a consequence of a rise of COVID-19 cases resulting in an R value greater than one, indicating that more than one new infection is caused by a single infected individual. Left unaddressed, this would result in a potentially massive increase in the number of cases to levels that cannot be controlled, overwhelming the NHS, and resulting in hundreds of thousands…